MedCity News April 13, 2021
Stephanie Baum

Peter Meath, Co-Head of Healthcare and Life Sciences for Middle Market Commercial Banking at J.P. Morgan, is bullish that the momentum will continue, particularly with investment trends focused on pain points amplified by the Covid-19 pandemic, from diagnostics development to supply chain management.

With the public health crisis causing widespread disruption to our lives, we were bracing for a downturn in investment last year that never came. Instead, the markets rallied around healthcare and life science companies and so did investors. In fact, venture capital investment in life sciences soared to a record high in the third quarter of last year. So what’s in store for 2021? Peter Meath, Co-Head of Healthcare and Life Sciences for Middle Market Commercial Banking...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Healthcare System, Investments, Pharma, Pharma / Biotech, Public Health / COVID, Trends
Former Bristol Myers CEO tapped as Novartis’ next board chair
The Power of Drug Discovery with Philip Tagari
Novartis raises forecasts as top drug sales beat Wall Street estimates
Pharma Pulse 4/23/24: Drug Discount Programs Poised to Change with New Tech, SpecialtyRx Savings Navigator to Enhance Affordability & more
AI Ushers in HPC Revival Says TACC’s Dan Stanzione

Share This Article